S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
These 5 Tech Stocks Have 10x Potential (Ad)pixel
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
These 5 Tech Stocks Have 10x Potential (Ad)pixel
Why CSL Ltd Stock Could Be Worth a Look
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
These 5 Tech Stocks Have 10x Potential (Ad)pixel
Closing prices for crude oil, gold and other commodities
EXPLAINER: What's the effect of Russian oil price cap, ban?
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
These 5 Tech Stocks Have 10x Potential (Ad)pixel
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
These 5 Tech Stocks Have 10x Potential (Ad)pixel
Why CSL Ltd Stock Could Be Worth a Look
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
These 5 Tech Stocks Have 10x Potential (Ad)pixel
Closing prices for crude oil, gold and other commodities
EXPLAINER: What's the effect of Russian oil price cap, ban?
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
These 5 Tech Stocks Have 10x Potential (Ad)pixel
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
These 5 Tech Stocks Have 10x Potential (Ad)pixel
Why CSL Ltd Stock Could Be Worth a Look
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
These 5 Tech Stocks Have 10x Potential (Ad)pixel
Closing prices for crude oil, gold and other commodities
EXPLAINER: What's the effect of Russian oil price cap, ban?
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
These 5 Tech Stocks Have 10x Potential (Ad)pixel
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
These 5 Tech Stocks Have 10x Potential (Ad)pixel
Why CSL Ltd Stock Could Be Worth a Look
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
These 5 Tech Stocks Have 10x Potential (Ad)pixel
Closing prices for crude oil, gold and other commodities
EXPLAINER: What's the effect of Russian oil price cap, ban?
NASDAQ:AVXL

Anavex Life Sciences - AVXL Stock Forecast, Price & News

$12.05
+3.18 (+35.85%)
(As of 12/2/2022 12:00 AM ET)
Add
Compare
Today's Range
$10.66
$13.23
50-Day Range
$8.82
$14.43
52-Week Range
$7.13
$20.24
Volume
45.68 million shs
Average Volume
1.45 million shs
Market Capitalization
$939.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$41.00

Anavex Life Sciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
348.1% Upside
$54.00 Price Target
Short Interest
Bearish
13.05% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.83
Upright™ Environmental Score
News Sentiment
0.55mentions of Anavex Life Sciences in the last 14 days
Based on 16 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.27) to $15.13 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.03 out of 5 stars

Medical Sector

628th out of 1,034 stocks

Biological Products, Except Diagnostic Industry

96th out of 171 stocks

AVXL stock logo

About Anavex Life Sciences (NASDAQ:AVXL) Stock

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Receive AVXL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anavex Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

AVXL Stock News Headlines

Berenberg Bank Reaffirms Their Buy Rating on Anavex Life Sciences (AVXL)
Why Anavex Life Sciences Stock Is Surging Today
Anavex Life Sciences Shares Down 17% On Wider 4Q Loss
Earnings Preview: Anavex Life Sciences
Anavex Life Sciences At A Pivotal Moment
Anavex Life Sciences Corp. (AVXL)
See More Headlines
Receive AVXL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anavex Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

AVXL Company Calendar

Last Earnings
11/24/2021
Today
12/03/2022
Next Earnings (Estimated)
2/07/2023
Fiscal Year End
9/30/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AVXL
Fax
N/A
Employees
25
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$54.00
High Stock Price Forecast
$80.00
Low Stock Price Forecast
$40.00
Forecasted Upside/Downside
+240.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-37,910,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.83 per share

Miscellaneous

Free Float
69,386,000
Market Cap
$939.42 million
Optionable
Optionable
Beta
0.71

Key Executives

  • Christopher U. Missling
    Chairman, President, CEO & Secretary
  • Stephan Toutain
    Chief Operating Officer
  • Sandra Boenisch
    Chief Financial Officer & Treasurer
  • Walter E. Kaufmann
    Chief Scientific Officer
  • Edward R. Hammond
    Chief Medical Officer













AVXL Stock - Frequently Asked Questions

Should I buy or sell Anavex Life Sciences stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Anavex Life Sciences in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AVXL shares.
View AVXL analyst ratings
or view top-rated stocks.

What is Anavex Life Sciences' stock price forecast for 2023?

2 equities research analysts have issued twelve-month price targets for Anavex Life Sciences' stock. Their AVXL share price forecasts range from $40.00 to $80.00. On average, they expect the company's share price to reach $54.00 in the next twelve months. This suggests a possible upside of 348.1% from the stock's current price.
View analysts price targets for AVXL
or view top-rated stocks among Wall Street analysts.

How have AVXL shares performed in 2022?

Anavex Life Sciences' stock was trading at $17.34 at the beginning of the year. Since then, AVXL shares have decreased by 30.5% and is now trading at $12.05.
View the best growth stocks for 2022 here
.

When is Anavex Life Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 7th 2023.
View our AVXL earnings forecast
.

How were Anavex Life Sciences' earnings last quarter?

Anavex Life Sciences Corp. (NASDAQ:AVXL) announced its quarterly earnings results on Wednesday, November, 24th. The biotechnology company reported ($0.15) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.15). During the same quarter in the previous year, the firm earned ($0.10) EPS.

What other stocks do shareholders of Anavex Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Anavex Life Sciences investors own include Inovio Pharmaceuticals (INO), POET Technologies (POETF), Brainstorm Cell Therapeutics (BCLI), LadRx (CYTR), Sanchez Energy (SN), Novavax (NVAX), Geron (GERN), VASCO Data Security International (VDSI), Sorrento Therapeutics (SRNE) and OPKO Health (OPK).

What is Anavex Life Sciences' stock symbol?

Anavex Life Sciences trades on the NASDAQ under the ticker symbol "AVXL."

Who are Anavex Life Sciences' major shareholders?

Anavex Life Sciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.82%), State Street Corp (5.60%), Vanguard Group Inc. (5.27%), Silverarc Capital Management LLC (0.00%), Renaissance Technologies LLC (0.47%) and Nuveen Asset Management LLC (0.35%). Insiders that own company stock include Athanasios Skarpelos, Elliot Favus, Elliot Favus, Peter DO Donhauser and Sandra Boenisch.
View institutional ownership trends
.

How do I buy shares of Anavex Life Sciences?

Shares of AVXL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Anavex Life Sciences' stock price today?

One share of AVXL stock can currently be purchased for approximately $12.05.

How much money does Anavex Life Sciences make?

Anavex Life Sciences (NASDAQ:AVXL) has a market capitalization of $939.42 million. The biotechnology company earns $-37,910,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis.

How can I contact Anavex Life Sciences?

Anavex Life Sciences' mailing address is 51 W 52ND STREET 7TH FLOOR, NEW YORK NY, 10019. The official website for the company is www.anavex.com. The biotechnology company can be reached via phone at (844) 689-3939 or via email at ir@anavex.com.

This page (NASDAQ:AVXL) was last updated on 12/3/2022 by MarketBeat.com Staff